A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.

ABSTRACT: The recent evolution of molecular targeted therapy has improved clinical outcomes in several human malignancies. The translocation of anaplastic lymphoma kinase (ALK) was originally identified in anaplastic large-cell lymphoma (ALCL) and subsequently in non-small cell lung carcinoma (NSCLC). Since ALK fusion gene products act as a driver of carcinogenesis in both ALCL and NSCLC, several ALK tyrosine kinase inhibitors (TKIs) have been developed. Crizotinib and alectinib are first- and second-generation ALK TKIs, respectively, approved for the treatment of ALK-positive ALCL (ALK⁺ ALCL) and ALK⁺ NSCLC. Although most ALK⁺ NSCLC patients respond to crizotinib and alectinib, they generally relapse after several years of treatment. We previously found that

SUBMITTER: Kawasoe K 

PROVIDER: S-EPMC10605931 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature